Erratum: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells (International Journal of Cancer (2015) 119 (1586-1598) DOI: 10.1002/ijc.22031);Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells

International Journal of Cancer

Volumn 119, Issue 7, 2006, Pages 1586-1598

  Narayanan, Narayanan K ^a   Narayanan, Bhagavathi A ^a   Bosland, Maarten ^a   Condon, Mark S ^b   Nargi, Dominick ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY Dutchess Community College   (United States)

Author keywords

COX 2 inhibitor; Docosahexaenoic acid; n 3 PUFA; Prostate cancer; Proteomics

Indexed keywords

CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; HEAT SHOCK PROTEIN 70; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN P53; TESTOSTERONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; LOW DRUG DOSE; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEOMICS; RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 33747508118     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29941     Document Type: Erratum

References (73)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ, Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Schloss I, Kidd MS, Tichelaar HY, Young GO, O'Keefe SJ. Dietary factors associated with a low risk of colon cancer in coloured West coast fishermen. S Afr Med J 1997;87:152-8.
3. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 1999;81:1238-42.
4. Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 2003;77:532-43.
5. Dewailly E, Mulvad G, Sloth Pedersen H, Hansen JC, Behrendt N, Hart Hansen JP. Inuit are protected against prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:926,927.
6. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of ω3/ω-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001;58:283-8.
7. Chung BH, Mitchell SH, Zhang JS, Young CY. Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 2001;22:1201-6.
8. Narayanan NK, Narayanan BA, Reddy BS. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-κB, and steroid hormone receptors. Int J Oncol 2005;26:785-92.
9. Rose DP, Cohen LA. Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis 1988;9:603-5.
10. Calviello G, Palozza P, Maggiano N, Piccioni E, Franceschelli P, Frattucci A, Di Nicuolo F, Bartoli GM. Cell proliferation, differentiation, and apoptosis are modified by n-3 polyunsaturated fatty acids in normal colonic mucosa. Lipids 1999;34:599-604.
11. Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS. n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol 2001;280: C1066-C1075.
12. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;2:3-16.
13. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78-83.
14. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54:467-72.
15. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-6.
16. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8.
17. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000;56:671-6.
18. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, Lalani EN. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736-41.
19. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma: relationship to apoptosis and Bcl-2 protein expression. Anticancer Res 2000;20:2313-9.
20. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-23.
21. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM, Breyer MD, Brash AR. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001;3:287-303.
22. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun 2005;332:800-7.
23. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
24. Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 2002;4:91-7.
25. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-33.
26. Liu G, Ma WY, Bode AM, Zhang Y, Dong Z. NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. J Biol Chem 2003;278:2124-30.
27. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-50.
28. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-7.
29. Rainsford KD. The ever-emerging anti-inflammatories. Have there been any real advances? J Physiol Paris 2001;95:11-19.
30. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81.
31. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643-52.
32. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
33. Grau MV, Baron JA, Barry EL, Sandler RS, Haile RW, Mandel JS, Cole BF. Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2005;14:2353-8.
34. Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in co-3 polyunsaturated fatty acids. Cancer Res 2005;65:8022-7.
35. Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004;127:838-44.
36. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005;115:484-92.
37. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.
38. Vabulas RM, Ahmad-Nejad P, Chose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277:15107-12.
39. Li WX, Chen CH, Ling CC, Li GC. Apoptosis in heat-induced cell killing: the protective role of hsp-70 and the sensitization effect of the c-myc gene. Radiat Res 1996;145:324-30.
40. Nylandsted J, Jaattela M, Hoffmann EK, Pedersen SF. Heat shock protein 70 inhibits shrinkage-induced programmed cell death via mechanisms independent of effects on cell volume-regulatory membrane transport proteins. Pflugers Arch 2004;449:175-85.
41. Chen YC, Kuo TC, Lin-Shiau SY, Lin JK. Induction of HSP70 gene expression by modulation of Ca(+2) ion and cellular p53 protein by curcumin in colorectal carcinoma cells. Mol Carcinog 1996;17:224-34.
42. Wang MH, Grossmann ME, Young CY. Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer 2004;90:926-31.
43. Lipinski KS, Pelech S, Mountain A, Irvine AS, Kraaij R, Bangma CH, Mills KH, Todryk SM. Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol Immunother 2006;55:347-54.
44. Condon MS, Kaplan LA, Crivello JF, Horton L, Bosland MC. Multiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated with N-methyl-N-nitrosourea and testosterone. Mol Carcinog 1999;25:179-86.
45. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.
46. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-W-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003;9:3503-13.
47. Narayanan NK, Narayanan BA. Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate- polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detect Prev 2004;28:443-52.
48. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
49. O'Farrell PH. High-resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-21.
50. Miller RG. Simultaneous statistical inference, 2nd edn. New York: Springer-Verlag, 1981. 37 p.
51. Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 1998;80:183-201.
52. Bonay M, Soler P, Riquet M, Battesti JP, Hance AJ, Tazi A. Expression of heat shock proteins in human lung and lung cancer. Am J Respir Cell Mol Biol 1994;10:453-61.
53. Lazaris AC, Chatzigianni EB, Panoussopoulos D, Tzimas GN, Davaris PS, Golematis BC. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 1997;43:43-51.
54. Gress TM, Muller-Pillasch F, Weber C, Lerch MM, Friess H, Buchler M, Beger HG, Adler G. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res 1994;54:547-51.
55. Kaur J, Ralhan R. Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer 1995;63:774-9.
56. Kamishima T, Fukuda T, Usuda H, Takato H, Iwamoto H, Kaneko H. Carcinogenesis of the urinary bladder: expression of epithelial and sarcomatous elements. Pathol Int 1997;47:166-73.
57. Narayanan BA, Narayanan NK, Simi B, Reddy BS. Modulation of inducible nitric oxide synthase and related pro-inflammatory genes by the ω-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res 2003;63:972-9.
58. Bartek J, Staskova Z, Lukas J, Bartkova J. Aberrations of the p53 anti-oncogene in malignant tumors. Cas Lek Cesk 1992;131:737-40.
59. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990;76:655-63.
60. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
61. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-9.
62. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.
63. Narayanan BA, Narayanan NK, Pittman P, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by non-steroidal anti-inflammatory drugs is linked to the sequential effect on androgen receptor, vasculoendothelial growth factor, cyclooxygenases and AKT signaling in TRAMP model. Clin Cancer Res 2004;10:7727-37.
64. Cappello F, David S, Rappa F, Bucchieri F, Marasa L, Bartolotta TE, Farina F, Zummo G. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastases. BMC Cancer 2005;5:139.
65. Maehara Y, Oki E, Abe T, Tokunaga E, Shibahara K, Kakeji Y, Sugimachi K. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer. Oncology 2000;58:144-51.
66. Ito A, Honda H, Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother 2006;55:320-8.
67. Ishihara K, Yamagishi N, Hatayama T. Suppression of heat- and polyglutamine-induced cytotoxicity by nonsteroidal anti-inflammatory drugs. Eur J Biochem 2004;271:4552-8.
68. Komarova EA, Neznanov N, Komarov PG, Chemov MV, Wang K, Gudkov AV. p53 inhibitor pifithrin α can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem 2003;278:15465-8.
69. Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M, Pratt WB. Pifithrin-α inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 2004;279:30195-201.
70. Tanimura S, Kohno M. Heat shock protein 70 binding protein 1 induces enhanced apoptotic response against anticancer drugs in tumor cells. Nippon Rinsho 2004;62:1291-6.
71. Kaur J, Srivastava A, Ralhan R. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer 1997;74:609-13.
72. Yeo M, Park HK, Kim DK, Cho SW, Kim YS, Cho SY, Paik YK, Hahm KB. Restoration of heat shock protein70 suppresses gastric mucosal inducible nitric oxide synthase expression induced by Helicobacter pylori. Proteomics 2004;4:3335-42.
73. Baryshev M, Sargsyan E, Wallin G, Lejnieks A, Furudate S, Hishinuma A, Mkrtchian S. Unfolded protein response is involved in the pathology of human congenital hypothyroid- goiter and rat non-goitrous congenital hypothyroidism. J Mol Endocrinol 2004;32:903-20.